A5065031244- Bladder and Urothelial Cancer Treatments
- Urinary and Genital Oncology Studies
- Urological Disorders and Treatments
- Esophageal Cancer Research and Treatment
- Cancer Immunotherapy and Biomarkers
- Renal and Vascular Pathologies
- Colorectal Cancer Screening and Detection
- Organ Donation and Transplantation
- Epigenetics and DNA Methylation
- Testicular diseases and treatments
- Urologic and reproductive health conditions
- Organ Transplantation Techniques and Outcomes
- Renal Transplantation Outcomes and Treatments
- Prostate Cancer Treatment and Research
- Urinary Bladder and Prostate Research
- Hemodynamic Monitoring and Therapy
- Urinary Tract Infections Management
- Ureteral procedures and complications
- Dietary Effects on Health
- Infectious Disease Case Reports and Treatments
- Genital Health and Disease
- Prostate Cancer Diagnosis and Treatment
- Pediatric Urology and Nephrology Studies
- Thyroid and Parathyroid Surgery
- Neurological Complications and Syndromes
Nara Medical University
2020-2025
Real-world evidence regarding enfortumab vedotin for unresectable or metastatic urothelial carcinoma is scarce, particularly in Japan. We investigated real-world data focusing on patient background, previous treatments, response, survival and adverse events patients receiving vedotin.
Chemotherapy drugs, such as gemcitabine and cisplatin (GC), are frequently administered to patients with advanced urothelial carcinoma, however the influence of gut microbiota on their action is unclear. Thus, we investigated effects GC microbiome determined whether oral supplementation a probiotics mixture Lactobacillus casei Shirota Bifidobacterium breve enhanced anti-tumor immune response. After subcutaneous inoculation MBT2 murine bladder cancer cells, syngenic C3H mice were randomly...
Clinical evidence regarding risk reduction of repeated bladder recurrence after initial photodynamic diagnosis (PDD)-assisted transurethral resection tumor (TURBT) is still limited in patients with non-muscle-invasive cancer (NMIBC). We analyzed primary NMIBC undergoing TURBT without any adjuvant treatment to compare the cumulative between conventional white-light (WL)-TURBT and PDD-TURBT. Out 430 diagnosed from 2010 2019, 40 WL-TURBT 60 PDD-TURBT were eligible. Multivariate Cox regression...
Abstract Objective To develop the first Japanese real-world evidence of switch-maintenance avelumab in advanced, unresectable or metastatic urothelial carcinoma (aUC). Methods A multicenter-derived database registered 505 patients diagnosed with aUC between 2008 and 2021. Of these, 204 (40%) were selected stratified according to type therapy used: maintenance group (27 [5.3%]), second-line (2 L) pembrolizumab (103 [20%]) 2 L cytotoxic chemotherapy (74 [15%]). The progression-free survival...
The objective of this study is to validate the predictive ability 2021 European Association Urology (EAU) risk model compared that existing models, including 2019 EAU and scoring tables Organization for Research Treatment Cancer, Club Urologico Espanol de Tratamiento Oncologico, Japanese Nishinihon Uro-oncology Extensive Collaboration Group. This retrospective multi-institutional database included two cohorts-3024 patients receiving intravesical bacillus Calmette-Guerin (BCG) treatment (BCG...
To explore possible solutions to overcome chronic Bacillus Calmette-Guérin (BCG) shortage affecting seriously the management of non-muscle invasive bladder cancer (NMIBC) in Europe and throughout world, we investigated whether non-maintenance eight-dose induction BCG (iBCG) was comparable six-dose iBCG plus maintenance (mBCG).This observational study evaluated 2669 patients with high- or highest-risk NMIBC who treated without mBCG during 2000-2019. The were classified into five groups...
The treatment landscape for advanced, unresectable, or metastatic urothelial carcinoma (aUC) has shifted substantially since the advent of immune checkpoint inhibitors (ICIs). We investigated extent to which pembrolizumab therapy is superior conventional chemotherapy as a second-line treatment.A multicenter-derived database registered 454 patients diagnosed with aUC between 2008 and 2020. Of these, 94 (21%) who received 75 (17%) but never third-line later ICI were included. compared overall...
The objective of this work is to evaluate the additional oncological benefit photodynamic diagnosis (PDD) using blue-light cystoscopy in transurethral resection (TURBT) for primary non-muscle-invasive bladder cancer (NMIBC) based on International Bladder Cancer Group (IBCG)-defined progression and subsequent pathological pathways.We reviewed 1578 consecutive NMIBC patients undergoing white-light TURBT (WL-TURBT) or PDD-TURBT during 2006-2020. One-to-one propensity score-matching was...
To investigate the organ-specific response and clinical outcomes of mixed responses (MRs) to immune checkpoint inhibitors (ICIs) for unresectable or metastatic urothelial carcinoma (ur/mUC), we retrospectively analyzed 136 patients who received pembrolizumab. The total objective rate (ORR) ORR were determined each lesion according Response Evaluation Criteria in Solid Tumors version 1.1 as follows: (i) complete (CR), (ii) partial (PR), (iii) stable disease (SD), (iv) progressive (PD). Most...
Complete metastasectomy (CM) in metastatic renal cell carcinoma (mRCC) has demonstrated efficacy the cytokine era, but its effectiveness era of tyrosine kinase inhibitors (TKIs) and immune checkpoint (ICIs) remains unclear. A multi-institutional database included clinicopathological data 367 patients with mRCC. Patients were divided into two groups: CM group non-CM group. These groups compared before after propensity score matching (PSM). Cox proportional hazard models used to detect factors...
A time-course questionnaire survey using the chemotherapy-induced taste alteration scale (CiTAS) was conducted in patients with advanced urothelial carcinoma (UC) treated systemic chemotherapy and/or immunotherapy. total of 37 receiving therapy enfortumab vedotin (EV), platinum-based and immune checkpoint inhibitors were included this study. No significant changes observed any CiTAS subscales during inhibitor treatment, while EV induced dysgeusia. Among 10 EV, dysgeusia associated a...
Abstract Objectives To validate the risk stratification newly defined in Japanese Urological Association guidelines 2019 for non‐muscle invasive bladder cancer and provide a more accurate model heterogeneous intermediate‐risk group. Methods A total of 1610 patients, who underwent transurethral resection, diagnosed with nine collaborating hospitals were retrospectively reviewed. They classified into low‐risk, intermediate‐risk, high‐risk, highest‐risk groups, recurrence‐free survival,...
Background: We describe the oncologic and functional outcomes surgical technique of photodynamic diagnosis (PDD)-assisted en bloc transurethral resection bladder tumor (EBTUR) using a rectangular cutting loop. Methods: reviewed 40 patients with carcinoma in situ-free nonmuscle invasive cancer undergoing PDD-TURBT. Of patients, 12 underwent diagnosis-assisted (PDD-EBTUR) 28 PDD-assisted conventional TURBT (cTURBT). Two groups were matched terms clinicopathologic background did not include...
Abstract Background Safety and survival during after donor nephrectomy (DN) are one of the main concerns in living kidney donors (LKDs). Therefore, (left/right) to be procured should determined considering difficulty DN, as well preservation remnant renal function (RRF). In this prospective study, we investigated roles computed tomography volumetry (CTV) split (SRF) established a predictive model for RRF LKDs. Methods We assessed 103 LKDs who underwent DN at our institute. The Volume...
Bladder cancer, especially non-muscle invasive bladder cancer (NMIBC), is one of the most costly cancers owing to its long-term management. Photodynamic diagnosis-assisted transurethral resection tumor (PDD-TURBT) reduces risk intravesical recurrence. However, impact on healthcare economics in Japan remains unclear. We evaluated comprehensive medical costs Japanese regarding PDD-TURBT.This large-scale, multicenter, retrospective study included a dataset 1531 patients who were diagnosed with...